Cannara Biotech Inc.

Total Valuation

Cannara Biotech Inc. carries a market capitalization of 175.83M, placing it among publicly traded companies globally. Its enterprise value stands at 189.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Cannara Biotech Inc. currently has 98.78M shares outstanding.

Valuation Ratios

Cannara Biotech Inc. trades at a trailing price-to-earnings ratio of 17.46. The price-to-sales ratio is 1.57, and the price-to-book ratio stands at 1.66.

Enterprise Valuation

On an enterprise value basis, Cannara Biotech Inc. trades at an EV/EBITDA multiple of 7.85 and an EV/FCF ratio of 4.62. The EV/Sales ratio of 1.68 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.68 provides insight into valuation relative to core operating earnings.

Financial Position

Cannara Biotech Inc. maintains a current ratio of 3.06, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 28.47, indicating elevated leverage, while an interest coverage ratio of 8.48 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Cannara Biotech Inc. posts a return on equity of 10.99 and a return on invested capital of 7.64.

Taxes

Over the trailing twelve months, Cannara Biotech Inc. has paid 5.04M in income taxes, reflecting an effective tax rate of 33.15.

Stock Price Statistics

Cannara Biotech Inc.'s stock has gained approximately 14.10256% over the past 52 weeks. The 50-day moving average sits at 1.71, while the 200-day moving average is 1.76.

Income Statement

Over the trailing twelve months, Cannara Biotech Inc. generated 112.84M in revenue and converted that into 10.16M in net income, yielding earnings per share of 0.11. EBITDA reached 24.15M, while operating income came in at 17.77M.

Balance Sheet

Cannara Biotech Inc. holds 21.90M in cash and equivalents against 34.22M in total debt, resulting in a net debt position of 12.08M. Total book value stands at 106.98M, with working capital of 61.34M providing operational flexibility.

Cash Flow

Cannara Biotech Inc. produced 27.64M in operating cash flow over the past twelve months. After subtracting -11.53M in capital expenditures, free cash flow totaled 16.11M - equivalent to 0.17 per share.

Margins

Cannara Biotech Inc. operates with a gross margin of 42.38, reflecting its pricing power and cost economics. The operating margin of 15.74 and net profit margin of 9.00 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Cannara Biotech Inc.'s most recent stock split took place on February 13, 2023 with a 10:1 split ratio.

Scores

Cannara Biotech Inc. posts an Altman Z-Score of 3.10, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.